Send me real-time posts from this site at my email
Motley Fool

Why Shares of MiMedx Are Collapsing Today

What happened

Shares of MiMedx Group (NASDAQ: MDXG) are down more than 60% as of 12:15 p.m. EDT today after a pair of clinical trials failed to demonstrate their intended benefits.

So what

The biotech focuses on regenerative medicine using amniotic tissue as a platform. The results today were from trials employing its micronized dehydrated human amnion chorion membrane (mdHACM).

The first was a phase 2b study to treat knee osteoarthritis (KOA). The study will officially conclude in October. But the 446 patients enrolled did not produce a statistically significant difference between those treated with the company's product and those treated with a placebo. There was also no statistically significant difference between a cohort of patients evaluated at the three-month or six-month end point.

Image source: Getty Images.

The second disappointment was a phase 3 trial for the treatment of plantar fasciiitis (PF). In the trial, patients treated with the MiMedx product and a placebo demonstrated the same improvements. Without a difference, there is no evidence the treatment works.

Now what

After the data, management has decided to shelve the PF trials. It will instead focus its efforts on additional analysis and a phase 3 study of the KOA treatment.

Despite not meeting its primary end points, the KOA study did show some differentiation in efficacy between patient cohorts. The company will meet with the Food and Drug Administration to chart a path forward for confirmatory studies.

Management said it now expects a pair of phase 3 studies will be required prior to filing for approval. Before today's news, MiMedx had estimated the application would be made in late 2024 or early 2025. That plan likely just got delayed, a lot more expensive, or both.

10 stocks we like better than MiMedx Group
When our award-winning analyst team has a stock tip, it can pay to listen. After all, the newsletter they have run for over a decade, Motley Fool Stock Advisor, has tripled the market.*

They just revealed what they believe are the ten best stocks for investors to buy right now... and MiMedx Group wasn't one of them! That's right -- they think these 10 stocks are even better buys.

See the 10 stocks

*Stock Advisor returns as of August 9, 2021

Jason Hawthorne has no position in any of the stocks mentioned. The Motley Fool has no position in any of the stocks mentioned. The Motley Fool has a disclosure policy.


Popular posts

Welcome! Is it your First time here?

What are you looking for? Select your points of interest to improve your first-time experience:

Apply & Continue